GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » Beneish M-Score

ZyVersa Therapeutics (ZyVersa Therapeutics) Beneish M-Score : 0.00 (As of Jun. 09, 2024)


View and export this data going back to 2022. Start your Free Trial

What is ZyVersa Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for ZyVersa Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 4 years, the highest Beneish M-Score of ZyVersa Therapeutics was 0.00. The lowest was 0.00. And the median was 0.00.


ZyVersa Therapeutics Beneish M-Score Historical Data

The historical data trend for ZyVersa Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZyVersa Therapeutics Beneish M-Score Chart

ZyVersa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - -

ZyVersa Therapeutics Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ZyVersa Therapeutics's Beneish M-Score

For the Biotechnology subindustry, ZyVersa Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZyVersa Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's Beneish M-Score falls into.



ZyVersa Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ZyVersa Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $2.90 Mil.
Total Assets was $21.65 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.01 Mil.
Selling, General, & Admin. Expense(SGA) was $9.99 Mil.
Total Current Liabilities was $9.58 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -2.827 + -13.339 + -2.902 + -78.513 = $-97.58 Mil.
Non Operating Income was 0 + -12.158 + 0 + -81.175 = $-93.33 Mil.
Cash Flow from Operations was -3.777 + -2.787 + -0.936 + -0.408 = $-7.91 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $2.84 Mil.
Total Assets was $114.95 Mil.
Property, Plant and Equipment(Net PPE) was $0.09 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.01 Mil.
Selling, General, & Admin. Expense(SGA) was $8.84 Mil.
Total Current Liabilities was $8.58 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0) / (0 / 0)
= /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (0 / 0)
= /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2.9 + 0.004) / 21.651) / (1 - (2.835 + 0.091) / 114.954)
=0.865872 / 0.974546
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.011 / (0.011 + 0.091)) / (0.012 / (0.012 + 0.004))
=0.107843 / 0.75
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(9.991 / 0) / (8.84 / 0)
= /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 9.583) / 21.651) / ((0 + 8.578) / 114.954)
=0.442612 / 0.074621
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-97.581 - -93.333 - -7.908) / 21.651
=0.169045

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


ZyVersa Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of ZyVersa Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ZyVersa Therapeutics (ZyVersa Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are 1) Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. 2) IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Executives
Pablo A. Guzman officer: Chief Medical Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Katrin Rupalla director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Stephen C. Glover director, officer: Chief Executive Officer 108 DOCKSIDE CIRCLE, WESTON FL 33327
Labella Nicholas A. Jr. officer: Chief Scientific Officer C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235
Peter Wolfe officer: Chief Financial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Karen A. Cashmere officer: Chief Commercial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Min-chul Park director C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Incon Co., Ltd. 10 percent owner 4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042
Robert G Finizio director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Raj Mehra director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
David S. Briones director, officer: Chief Financial Officer C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Daniel J. O'connor director, officer: Chief Executive Officer C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
A.g.p. / Alliance Global Partners Corp. 10 percent owner 88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880

ZyVersa Therapeutics (ZyVersa Therapeutics) Headlines

From GuruFocus

ZyVersa Therapeutics Announces Changes to ZyVersa's Board of Directors

By GlobeNewswire GlobeNewswire 05-19-2023